Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 269-272

  Kentsch, M ^a   Otter, W ^a   Drummer, C ^b   Notges A ^c   Gerzer, R ^b   Muller Esch G ^a  

^a Klinikum der Hansestadt Stralsund   (Germany)

^b GERMAN AEROSPACE CENTER DLR   (Germany)

^c Herz Kreislauf Klinik   (Germany)

Author keywords

antagonists and inhibitors; atrial; congestive heart failure; cyclic GMP; haemodynamics; metalloproteinases; neutral endopeptidase 24.11; natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CANDOXATRIL; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; HEART INDEX; HEMODYNAMICS; HUMAN; NATRIURESIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VASCULAR RESISTANCE; VASODILATATION;

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CYCLIC AMP; DOUBLE-BLIND METHOD; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INDANS; MIDDLE AGED; NEPRILYSIN; PROPIONATES; PROTEASE INHIBITORS;

EID: 0030444541     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050196     Document Type: Article

References (18)

1. Danilewicz JC, Barclay PL, Barnish IT, Brown D, Campbell SF, James K, Samuels GM, Terrett NK, Wythes MJ (1989) UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun 164:58-65
2. Gros C, Souque A, Schwartz JC, Duchier J, Cournot A, Baumer P, Lecomte JM (1989) Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan. Proc Natl Acad Sci USA 86:7580-7584
3. Smits GJ, McGraw DE, Trapani AJ, Blaine EB (1990) Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters. J Pharmacol Exp Ther 254:176-179
4. Tikkanen I, Helin K, Tikkanen T, Sybertz EJ, Vemulapalli S, Sariola H, Naveri H, Fyhrquist F (1990) Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther 254:641-645
5. Motwani JG, Lang CC, Allen MJ, Johnson HF, Struthers AD (1993) Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther 54:661-669
6. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, Cussans N (1990) Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 16:269-276
7. Northridge DB, Jardine AG, Findlay IN, Archibald M, Dilly SG, Dargie HJ (1990) Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am J Hypertens 3:682-687
8. Kentsch M, Ludwig D, Drummer C, Gerzer R, Müller-Esch G (1992) Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest 22:662-669
9. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C (1993) Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 11:407-416
10. Richards AM, Crozier IG, Kosoglou T, Rallings M, Espiner EA, Nicholls MG, Yandle TG, Ikram H, Frampton C (1993) Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 22:119-126
11. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT (1992) Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 10:607-613
12. Elsner D, Müntze A, Kromer EP, Riegger GA (1992) Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 70:494-498
13. Münzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, Drexler H (1992) Neurohormonal inhibition and haemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 86:1089-1098
14. Waxman L, Doshi KP, Gaul SL, Wang S, Bednar RA, Stern AM (1994) Identification and characterization of endothelin converting activity from EAHY 926 cells: evidence for the physiologically relevant human enzyme. Arch Biochem Biophys 308:240-253
15. Abassi ZA, Golomb E, Bridenbaugh R, Keiser HR (1993) Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br J Pharmacol 109:1024-1028
16. Edano T, Arai K, Ohshima T, Koshi T, Hirata M, Ohkuchi M, Okabe T (1994) Purification and characterization of endothelin-1 degradation activity from porcine kidney. Biol Pharm Bull 17:379-382
17. Edano T, Arai K, Koshi T, Torii T, Ohshima T, Hirata M, Ohkuchi M, Okabe T (1994) Digestion of endothelin-1 on cultured vascular smooth muscle cells. Biol Pharm Bull 17: 376-378
18. Kiowski W, Sutch G, Hunziker P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346:732-736